MYGN Financial Facts

Cost of molecular diagnostic testing: 32.8M
Operating income: 25.92M
See Full Income Statement

Total stockholders' equity: 712.15M
Long-term marketable investment securities: 54.07M
See Full Balance Sheet

Myriad Genetics Inc. (MYGN) Earnings

  |   Expand Research on MYGN
Next EPS Date 8/12/15 *Est. EPS Growth Rate -16.7% *Last Qtr.
Average EPS % Beat Rate -0.2% Revenue Growth Rate +2.2% *Last Qtr.
Average % Move 1-Wk after EPS -7.2% Normal Earnings Time After Close
Date  Qtr EPS Cons. Surprise Revs Cons. Gd. 1-Week % 1-Day % Details
5/5/15 Q315 $0.40$0.39 +$0.01$180M$183.3M Details
2/3/15 Q215 $0.40$0.35 +$0.05$184.4M$183.41M Details
11/4/14 Q115 $0.25$0.32 -$0.07$168.8M$175M Details
8/12/14 Q414 $0.48$0.46 +$0.02$188.8M$187.68M Details
5/6/14 Q314 $0.48$0.45 +$0.03$176.2M$175.23M = Details
2/4/14 Q214 $0.66$0.46 +$0.20$204.06M$176.02M = Details
11/5/13 Q114 $0.68$0.46 +$0.22$202.47M$167.64M = Details
8/13/13 Q413 $0.53$0.44 +$0.09$174.1M$159.87M = Details